Boostrix + Placebo (Saline)

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Prevention of Infections With Bordetella Pertussis

Conditions

Prevention of Infections With Bordetella Pertussis

Trial Timeline

Aug 24, 2015 → Dec 15, 2016

NCT ID

NCT02555540

About Boostrix + Placebo (Saline)

Boostrix + Placebo (Saline) is a approved stage product being developed by Novartis for Prevention of Infections With Bordetella Pertussis. The current trial status is completed. This product is registered under clinical trial identifier NCT02555540. Target conditions include Prevention of Infections With Bordetella Pertussis.

What happened to similar drugs?

8 of 20 similar drugs in Prevention of Infections With Bordetella Pertussis were approved

Approved (8) Terminated (0) Active (12)

✅RaltegravirMerckApproved

✅Meningococcal C conjugate vaccineNovartisApproved

✅Lenacapavir long-actingGilead SciencesApproved

✅DescovyGilead SciencesApproved

✅13-valent Pneumococcal conjugate vaccinePfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02555540	Approved	Completed	Aug 24, 2015	Dec 15, 2016	Prevention of Infections With Bordetella Pertussis

Competing Products

20 competing products in Prevention of Infections With Bordetella Pertussis

See all competitors

Product	Company	Stage	Hype Score
mRNA-1944	Moderna	Phase 1	0
Gam-COVID-Vac	Dr. Reddy's Laboratories	Phase 2/3	31
edoxaban + enoxaparin sodium	Daiichi Sankyo	Phase 3	40
Mifepristone	Eli Lilly	Phase 2	35
EXANTA	AstraZeneca	Phase 2	27
Risk of low dose aspirin discontinuation	AstraZeneca	Pre-clinical	26
DAPA/MET XR + DAPA + MET XR	AstraZeneca	Phase 3	40
Esomeprazole + Placebo	AstraZeneca	Phase 3	40
PCV15	Merck	Pre-clinical	18
Raltegravir	Merck	Approved	43
RotaTeq (V260) + IPV	Merck	Phase 3	40
V501	Merck	Phase 3	40
Zostavax	Merck	Phase 3	40
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920	Merck	Phase 3	40
Letermovir + Placebo	Merck	Phase 3	40
Meningococcal C conjugate vaccine	Novartis	Approved	43
Enteric-coated mycophenolate sodium	Novartis	Phase 3	40
Meningococcal C conjugate vaccine	Novartis	Approved	43
rMenB+OMV NZ	Novartis	Phase 3	40
Enteric-Coated Mycophenolate Sodium	Novartis	Phase 3	40